The Food and Drug Administration has given regulatory clearance for the use of Pfizer's Prevnar 13 vaccine in children between the ages of 6 and 17. Prevnar 13, a pneumococcal conjugate vaccine that protects against 13 strains of the bacteria Streptococcus pneumonaie, was first introduced into the U.S. in early 2010.
Nearly 120 countries have approved Prevnar 13 for use so far, and more than 500 million doses have been distributed across the globe. Sales continue to rise for Pfizer, with the vaccine scoring $3.72 billion in 2012. Analysts expect that number to jump to as much as $6.75 billion by 2018.
The article FDA Approves Extended Use of Pfizer's Prevnar 13 originally appeared on Fool.com.
Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.